Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
Protein & Cell
; (12): 573-589, 2017.
Article
en En
| WPRIM
| ID: wpr-756986
Biblioteca responsable:
WPRO
ABSTRACT
Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment that has recently been undergoing rapid development. However, there are still some major challenges, including precise tumor targeting to avoid off-target or "on-target/off-tumor" toxicity, adequate T cell infiltration and migration to solid tumors and T cell proliferation and persistence across the physical and biochemical barriers of solid tumors. In this review, we focus on the primary challenges and strategies to design safe and effective CAR T cells, including using novel cutting-edge technologies for CAR and vector designs to increase both the safety and efficacy, further T cell modification to overcome the tumor-associated immune suppression, and using gene editing technologies to generate universal CAR T cells. All these efforts promote the development and evolution of CAR T cell therapy and move toward our ultimate goal-curing cancer with high safety, high efficacy, and low cost.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Patología
/
Terapéutica
/
Trasplante
/
Proteínas Recombinantes de Fusión
/
Activación de Linfocitos
/
Receptores de Antígenos de Linfocitos T
/
Linfocitos T
/
Transducción de Señal
/
Expresión Génica
/
Movimiento Celular
Límite:
Humans
Idioma:
En
Revista:
Protein & Cell
Año:
2017
Tipo del documento:
Article